143 related articles for article (PubMed ID: 26982234)
1. 5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors.
Ai T; Wilson DJ; More SS; Xie J; Chen L
J Med Chem; 2016 Apr; 59(7):2928-41. PubMed ID: 26982234
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
Cui H; Kamal Z; Ai T; Xu Y; More SS; Wilson DJ; Chen L
J Med Chem; 2014 Oct; 57(20):8340-57. PubMed ID: 25275824
[TBL] [Abstract][Full Text] [Related]
3. 5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs.
Ai T; Wilson DJ; Chen L
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005376
[TBL] [Abstract][Full Text] [Related]
4. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
8. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.
Disch JS; Evindar G; Chiu CH; Blum CA; Dai H; Jin L; Schuman E; Lind KE; Belyanskaya SL; Deng J; Coppo F; Aquilani L; Graybill TL; Cuozzo JW; Lavu S; Mao C; Vlasuk GP; Perni RB
J Med Chem; 2013 May; 56(9):3666-79. PubMed ID: 23570514
[TBL] [Abstract][Full Text] [Related]
9. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.
Napper AD; Hixon J; McDonagh T; Keavey K; Pons JF; Barker J; Yau WT; Amouzegh P; Flegg A; Hamelin E; Thomas RJ; Kates M; Jones S; Navia MA; Saunders JO; DiStefano PS; Curtis R
J Med Chem; 2005 Dec; 48(25):8045-54. PubMed ID: 16335928
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies.
Chowdhury S; Sripathy S; Webster A; Park A; Lao U; Hsu JH; Loe T; Bedalov A; Simon JA
Molecules; 2020 Jan; 25(3):. PubMed ID: 31973227
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of 8-Mercapto-3,7-Dihydro-1
Han H; Li C; Li M; Yang L; Zhao S; Wang Z; Liu H; Liu D
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549218
[TBL] [Abstract][Full Text] [Related]
12. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
13. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
Outeiro TF; Kontopoulos E; Altmann SM; Kufareva I; Strathearn KE; Amore AM; Volk CB; Maxwell MM; Rochet JC; McLean PJ; Young AB; Abagyan R; Feany MB; Hyman BT; Kazantsev AG
Science; 2007 Jul; 317(5837):516-9. PubMed ID: 17588900
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
15. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.
Zhang Y; Au Q; Zhang M; Barber JR; Ng SC; Zhang B
Biochem Biophys Res Commun; 2009 Sep; 386(4):729-33. PubMed ID: 19559674
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Salo HS; Suuronen T; Poso A; Salminen A; Leppänen J; Jarho E; Lahtela-Kakkonen M
J Med Chem; 2011 Oct; 54(19):6456-68. PubMed ID: 21895016
[TBL] [Abstract][Full Text] [Related]
17. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
[TBL] [Abstract][Full Text] [Related]
18. N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors.
Kiviranta PH; Leppänen J; Rinne VM; Suuronen T; Kyrylenko O; Kyrylenko S; Kuusisto E; Tervo AJ; Järvinen T; Salminen A; Poso A; Wallén EA
Bioorg Med Chem Lett; 2007 May; 17(9):2448-51. PubMed ID: 17329104
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening approach of sirtuin inhibitors results in two new scaffolds.
Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M
Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698
[TBL] [Abstract][Full Text] [Related]
20. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A
Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
